AllSci News
Oryzon secures EUR 37m as LSD1 inhibitor iadademstat advances
Spain-based Oryzon Genomics, S.A. (Madrid: ORY) announced a completed equity capital increase of EUR 12 million (approximately USD 14.1 million) alongside a...
Arcutis expands Zoryve’s indication to youngest psoriasis patients after FDA nod
California-based Arcutis Biotherapeutics (Nasdaq: ARQT) has received US FDA approval to expand the indication for Zoryve (roflumilast) cream 0.3% to children as…
Natera embeds Signatera into Aveta’s Phase III head and neck cancer trial
Natera, Inc. (Nasdaq: NTRA) and Massachusetts-based Aveta Biomics, Inc. announced a clinical research collaboration integrating Natera’s Signatera tumor-informed circulating tumor DNA assay…
Larimar advances first Friedreich's ataxia drug toward accelerated FDA approval with novel surrogate endpoint
Bala Cynwyd, Pennsylvania-based Larimar Therapeutics (Nasdaq: LRMR) has submitted the first module of a rolling Biologics License Application (BLA) to the...
Viatris clears path to Japan NDA for VR-205 in IgA nephropathy
Viatris Inc. (Nasdaq: VTRS) reported positive top-line results from a Phase III bridging study of VR-205 (targeted-release budesonide) in Japanese adults...
Flare Therapeutics secures USD 85m Series C to advance prostate cancer degrader program
Cambridge, Massachusetts-based Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company focused on drugging transcription factors in...
Nuvectis replenishes coffers after Haisco deal with USD 100m public offering
Fort Lee, New Jersey-based Nuvectis Pharma, Inc. (Nasdaq: NVCT) announced the pricing of an underwritten public offering of common stock, raising USD 100...
FibroBiologics secures up to USD 9.0m in PIPE funds to extend runway
Houston-based FibroBiologics, Inc. (Nasdaq: FBLG) announced the closing of a private placement on June 29, 2026, raising USD 3.0 million in upfront gross...
Pyxis secures USD 114m to push MICVO toward dual clinical readouts in head and neck cancer
Boston-based Pyxis Oncology, Inc. (Nasdaq: PYXS) announced a private placement of up to USD 114 million to extend its cash runway into Q2 2027 and fund two...
Cogent advances bezuclastinib toward approval across three mastocytosis indications simultaneously
Cogent Biosciences (Nasdaq: COGT) has submitted its third New Drug Application to the US FDA in six months, filing for bezuclastinib in advanced systemic...
Moleculin's annamycin delivers three-fold remission advantage in relapsed AML interim analysis
Moleculin Biotech (Nasdaq: MBRX) reported that annamycin (naxtarubicin), its liposomal anthracycline candidate, produced complete remission rates roughly...
Abivax reports additional Phase III maintenance data supporting obefazimod in ulcerative colitis
Abivax (Nasdaq: ABVX) reported Phase III ABTECT maintenance results for obefazimod in moderately to severely active ulcerative colitis that demonstrated...
Abivax raises USD 600m to fuel US launch of obefazimod ahead of NDA submission
France-based Abivax SA (Euronext Paris: ABVX / Nasdaq: ABVX) announced the launch of an underwritten public offering of approximately USD 600 million (EUR...
Hanmi completes USD 41m-backed acquisition of Aptose, securing tuspetinib AML program
South Korea-based Hanmi Pharmaceutical Co., Ltd. has completed its acquisition of Aptose Biosciences Inc. (TSX: APS | OTC: APTOF), a clinical-stage oncology...
Mesoblast advances first cellular therapy for life-threatening LVAD complications
Australia-based Mesoblast Limited (ASX: MSB; Nasdaq: MESO) has received a Biologics License Application filing number from the US FDA and requested a...
The AllSci Brief
Systematic R&D and deal news. Daily.